Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Özgüroğlu Mustafa, Ahn Myung-Ju, Dong Xiaorong, Yang James Chih-Hsin, Oizumi Satoshi, Goto Koichi, Cobo Manuel, Kim Sang-We, Hsia Te-Chun, Chindaprasirt Jarin, Fujiki Fernanda, Valdiviezo Natalia, Casarini Ignacio, Kato Terufumi, Huang Xiangning, Evans Azura, Armenteros-Monterroso Elena, Bolanos Ana, Ramalingam Suresh S, Lu Shun
Аннотация
INTRODUCTION: In the phase III LAURA study, osimertinib demonstrated statistically significant improvement in progression-free survival (PFS) versus placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) without disease progression during/after chemoradiotherapy. We report pre-specified post-progression outcomes, subsequent treatments and a second interim analysis of overall survival (OS).
METHODS: Patients were randomized 2:1 to receive osimertinib or placebo until progression (blinded independent central review) or discontinuation. Open-label osimertinib was offered post-progression. Secondary endpoints included time to first and second subsequent treatment (TFST and TSST), second PFS (PFS2) and OS.
RESULTS: At primary data cutoff (January 5, 2024), TFST (hazard ratio [HR], 0.13; 95% CI, 0.08-0.21), PFS2 (0.62; 0.35-1.08) and TSST (0.51; 0.28-0.91) were improved with osimertinib versus placebo. As reported previously, 63/143 (44%) and 66/73 (90%) patients had discontinued randomized osimertinib and placebo treatment, respectively. The most common first subsequent systemic treatment was an EGFR-tyrosine kinase inhibitor in the osimertinib and placebo arms (22/63 [35%] and 56/66 [85%], respectively), primarily osimertinib (14/63 [22%] and 50/66 [76%]). At the second interim OS analysis (data cutoff: November 29, 2024), there was a trend towards OS benefit with osimertinib versus placebo (HR, 0.67; 95% CI, 0.40-1.14; 31% maturity).
CONCLUSIONS: Osimertinib demonstrated clinically meaningful improvements versus placebo in TFST, PFS2 and TSST, and a trend towards OS benefit. These data indicate that clinical benefit with osimertinib was preserved beyond first progression, supporting long-term benefits of osimertinib for unresectable stage III EGFR-mutated NSCLC without progression during/after definitive chemoradiotherapy.
METHODS: Patients were randomized 2:1 to receive osimertinib or placebo until progression (blinded independent central review) or discontinuation. Open-label osimertinib was offered post-progression. Secondary endpoints included time to first and second subsequent treatment (TFST and TSST), second PFS (PFS2) and OS.
RESULTS: At primary data cutoff (January 5, 2024), TFST (hazard ratio [HR], 0.13; 95% CI, 0.08-0.21), PFS2 (0.62; 0.35-1.08) and TSST (0.51; 0.28-0.91) were improved with osimertinib versus placebo. As reported previously, 63/143 (44%) and 66/73 (90%) patients had discontinued randomized osimertinib and placebo treatment, respectively. The most common first subsequent systemic treatment was an EGFR-tyrosine kinase inhibitor in the osimertinib and placebo arms (22/63 [35%] and 56/66 [85%], respectively), primarily osimertinib (14/63 [22%] and 50/66 [76%]). At the second interim OS analysis (data cutoff: November 29, 2024), there was a trend towards OS benefit with osimertinib versus placebo (HR, 0.67; 95% CI, 0.40-1.14; 31% maturity).
CONCLUSIONS: Osimertinib demonstrated clinically meaningful improvements versus placebo in TFST, PFS2 and TSST, and a trend towards OS benefit. These data indicate that clinical benefit with osimertinib was preserved beyond first progression, supporting long-term benefits of osimertinib for unresectable stage III EGFR-mutated NSCLC without progression during/after definitive chemoradiotherapy.